세계의 족저근막염 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)

The global demand for Plantar Fasciitis Treatment Market is presumed to reach the market size of nearly USD 1303.9 Million by 2032 from USD 838.35 Million in 2023 with a CAGR of 5.03% under the study period 2024 - 2032.

Plantar Fasciitis Treatment involves addressing plantar fascia inflammation which is a thick tissue band in the foot that causes heel pain. Treatment options may include rest, physical therapy, stretching exercises, orthotic devices, and anti-inflammatory medications.

MARKET DYNAMICS

The plantar fasciitis treatment market is influenced by the rising incidence of foot-related disorders and the growing awareness about effective treatment options. Plantar fasciitis prompts individuals to seek remedies, driving the demand for various treatment modalities. Factors such as an aging population, increased physical activity, and a surge in sports-related injuries contribute to the growth of the plantar fasciitis treatment market. Innovative treatments, including shockwave therapy, orthotic devices, and regenerative medicine approaches, further expand available options. Additionally, the impact of plantar fasciitis on daily life and mobility motivates individuals to explore and adopt diverse treatment solutions, boosting the overall market for plantar fasciitis treatments.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of plantar fasciitis treatment. The growth and trends of plantar fasciitis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the plantar fasciitis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Medication Therapy (Oral, Parenteral)
• Shockwave Therapy (Extracorporeal Shock Wave Therapy (ESWT), Intracorporeal Pneumatic Shockwave Therapy (IPST))
• Surgery
• Orthotics
• Others

By End-User

• Hospitals
• Clinics
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Plantar Fasciitis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Plantar Fasciitis Treatment market include Hanger, Inc., Bayer Group (Dr. Scholl's), A. Algeo Limited, Bauerfeind AG, Superfeet Worldwide, Inc., Ottobock SE & Co. KGaA (Ottobock Holding), Pfizer, Inc., Sanofi, GlaxoSmithKline plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PLANTAR FASCIITIS TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By End-user
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PLANTAR FASCIITIS TREATMENT MARKET ANALYSIS BY TYPE

• 5.1 Overview by Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Type
• 5.4 Medication Therapy (Oral, Parenteral) Historic and Forecast Sales by Regions
• 5.5 Shockwave Therapy (Extracorporeal Shock Wave Therapy (ESWT), Intracorporeal Pneumatic Shockwave Therapy (IPST)) Historic and Forecast Sales by Regions
• 5.6 Surgery Historic and Forecast Sales by Regions
• 5.7 Orthotics Historic and Forecast Sales by Regions
• 5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL PLANTAR FASCIITIS TREATMENT MARKET ANALYSIS BY END-USER

• 6.1 Overview by End-user
• 6.2 Historical and Forecast Data
• 6.3 Analysis by End-user
• 6.4 Hospitals Historic and Forecast Sales by Regions
• 6.5 Clinics Historic and Forecast Sales by Regions
• 6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL PLANTAR FASCIITIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PLANTAR FASCIITIS TREATMENT COMPANIES

• 8.1. Plantar Fasciitis Treatment Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF PLANTAR FASCIITIS TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Hanger Inc.
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Bayer Group (Dr. Scholl's)
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. A. Algeo Limited
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Bauerfeind AG
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Superfeet Worldwide Inc.
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Ottobock SE & Co. KGaA (Ottobock Holding)
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Pfizer Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Sanofi
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. GlaxoSmithKline Plc
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies